Community poverty and trends in racial/ethnic survival disparities among people diagnosed with AIDS in Florida, 1993-2004

American Journal of Public Health

Volumn 103, Issue 4, 2013, Pages 717-726

  Trepka, Mary Jo ^a   Niyonsenga, Theophile ^b   Maddox, Lorene ^b   Lieb, Spencer ^b   Lutfi, Khaleeq ^b   Pavlova McCalla, Elena ^b  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CHI SQUARE DISTRIBUTION; ETHNOLOGY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MALE; MIDDLE AGED; POVERTY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICS; SURVIVAL; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICAN AMERICANS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLORIDA; HUMANS; MALE; MIDDLE AGED; POVERTY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

MLCS; MLOWN;

EID: 84875195465     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2012.300930     Document Type: Article

References (68)

1. Centers for Disease Control and Prevention. HIV surveillance - United States, 1981-2008. MMWR Morb Mortal Wkly Rep. 2011;60(21):689-693, June 3, 2011. Available at: http://www.cdc.gov/mmwr/pdf/wk/mm6021.pdf. Accessed July 29, 2011.
2. Centers for Disease Control and Prevention. HIV Surveillance Report, 2009. Vol 21, February 2011. Available at: /http://www.cdcgov/hiv/survillance/ resources/reports/2009report. Accessed October 22, 2011.
3. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: Final Data for 2007. Natl Vital Stat Rep. 2010;58 (19):1-136. Available at http://www.cdc.gov/nchs/ data/nvsr/nvsr58/nvsr58-19.pdf. Accessed July 29, 2011.
4. Goodman AH. Why genes don't count (for racial differences in health). Am J Public Health. 2000;90(11): 1699-1702.
5. Kaplan JB, Bennett T. Use of race and ethnicity in biomedical publication. JAMA. 2003;289(20):2709-2716.
6. Giordano TP, Morgan RO, Kramer JR, et al. Is there a race-based disparity in the survival of veterans with HIV? J Gen Intern Med. 2006;21:613-617.
7. Silverberg MJ, Wegner SA, Milazzo MJ, et al. Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006;20:1531-1538.
8. Silverberg MJ, Leyden W, Quesenberry CP, Horberg MA Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med. 2009;24(9):1065-1072.
9. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;280(17):1497-1503.
10. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338(13):853-860.
11. Schneider MF, Gange SJ, Wiliams CM, et al. Patterns of the hazard of death after AIDS through the evolution of.antiretroviral therapy: 1984-2004. AIDS. 2005;19: 2009-2018.
12. Schwarcz SK, Hsu LC, Vittinghoff E, Katz MH. Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996. Am J Epidemiol. 2000;152(2):178-185.
13. Blair JM, Fleming PL, Karon JM. Trend in AIDS incidence and survival among racial/ethnic minority men who have sex with men, United States, 1990-1999. J Acquir Immune Defic Syndr. 2002;31(3):339-347.
14. Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US states, 1996-2004. PLoS ONE. 2009;4(2):e4445 Epub 2009 February 13.
15. Hall HI, Byers RH, Ling Q, Espinoza L. Racial/ethnic and age disparities in HIV prevalence and disease progression among men who have sex with men in the United States. Am J Public Health. 2007;97(6):1060-1066.
16. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr. 2010;53(1):124-130.
17. Nash D, Katyal M, Shah S. Trends in predictors of death due to HIV-related causes among persons living with AIDS in New York City: 1993-2001. J Urban Health. 2005;82(4):584-600.
18. Arnold M, Hsu L, Pipkin S, McFarland W, Rutherford GW. Race, place and AIDS: the role of socioeconomic context on racial disparities in treatment and survival in San Francisco. Soc Sci. Med. 2009;69: 121-128.
19. McFarland W, Chen S, Hsu L, Schwarcz S, Katz M Low socioeconomic status is associated with a higher rate of death in the era of highly active antiretroviral therapy, San Francisco. J Acquir Immune Defic. Syndr 2003;33:96-103.
20. Harrison KM, Ling Q, Song R, Hall HI. County-level socioeconomic status and survival after HIV diagnosis, United States. Ann Epidemiol. 2008;18(12):919-927.
21. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992; 41(RR-17):1-19, December 18, 1992. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ 00018871.htm. Accessed March 30, 2010.
22. Katz MH, Hsu L, Lingo M, Woelffer G, Schwarcz SK. Impact of socioeconomic status on survival with AIDS. Am J Epidemiol. 1998;148(3):282-291.
23. Hessol NA, Buchbinder SP, Colbert D, et al. Impact of HIV infection on mortality and accuracy of AIDS reporting on death certificates. Am J Public Health. 1992; 82(4):561-564.
24. US Census Bureau. Census. 2000 ZCTAs™, ZIP Code Tabulation Areas Technical Documentation. Available at: http://www.census.gov/geo/ZCTA/zcta-tech- doc.pdf. Accessed October 22, 2011.
25. Hosmer DW, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time-to-Event Data, 2nd Edition, 2008. New York, NY: A Wiley-Interscience Publication, John Wiley & Sons, Inc.
26. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526.
27. Chaix B, Rosval M, Merlo J. Recent increase of neighborhood socioeconomic effects on ischemic heart disease mortality: a multilevel survival analysis of two large Swedish cohorts. Am J Epidemiol. 2007; 165(1): 22-26.
28. SAS [computer program)]. Version 9.2, Cary, NC: SAS Institute, Inc, 2002-2008.
29. Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. Health Serv Res. 2000;35(2):389-416.
30. Bing EG, Kilbourne AM, Brooks RA, Lazarus EF, Senak M. Protease inhibitor use among a community sample of people with HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:474-480.
31. Cook JA, Cohen MH, Grey D, et al. Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health. 2002;92(1): 82-87.
32. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. J Acquir Immune Defic Syndr. 2000;25(2):115-123.
33. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States results from the HIV Cost and Services Utilization Study. JAMA. 1999;281(24):2305-2315.
34. Wong MD, Cunningham WE, Shapiro MF, et al. Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients. J Gen Intern Med. 2004;19(4): 366-374.
35. Anderson KH, Mitchell JM. Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Arch Intern Med. 2000; 160:3114-3120.
36. King WD, Minor P, Ramirez Kitchen C, et al. Racial, gender and geographic disparities of antiretroviral treatment among US Medicaid enrollees in 1998. J Epidemiol Community Health. 2008;62(9):798-803.
37. Sambamoorthi U, Moynihan PJ, McSpiritt E, Crystal S. Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid Beneficiaries with AIDS. Am J Public Health. 2001; 91(9):1474-1481.
38. Centers for Disease Control and Prevention. Late versus early testing of HIV-16 sites, United States, 2000-2003. MMWR Morb Mortal Wkly Rep. 2003;52 (25):581-586, June 27, 2003. Available at: http://www.cdc.gov/mmwr/PDF/wk/ mm5225.pdf. Accessed July 30, 2011.
39. Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005;39(5):537-544.
40. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005; 38(1):96-103.
41. Jain S, Schwarcz S, Katz M, Gulati R, McFarland W. Elevated risk of death for African Americans with AIDS, San Francisco, 1996-2002. J Health Care Poor Under-served. 2006;17:493-503.
42. Johnson MO, Catz SL, Remien RH, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. AIDS Patient Care STDS. 2003; 17(12):645-656.
43. Saha S, Jacobs EA, Moore RD, Beach MC. Trust in physicians and racial disparities in HIV care. AIDS Patient Care STDS. 2010;24(7):415-420.
44. Thrasher AD, Earp JAL, Golin CE, Zimmer CA. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49(1):84-93.
45. Bogart LM, Wagner GJ, Galvan FT, Klein DJ. Longitudinal relationships between antiretroviral treatment adherence and discrimination due to HIV-serostatus, race, and sexual orientation among African-American men with HIV. Ann Behav Med 2010;40:184-190.
46. Bogart LM, Catz SL, Kelly JA, Benotsch EG. Factors influencing physicians' judgments of adherence and treatment decisions for patients with HIV disease. Med Decis Making. 2001;21:28-36.
47. Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among African American men with HIV. J Acquir Immune Defic Syndr. 2010;53(5): 648-655.
48. Ebrahim SH, Anderson JE, Weidle P, Purcell DW. Race/ethnic disparities in HIV testing and knowledge about treatment for HIV/AIDS: United States, 2001. AIDS Patient Care STDS. 2004;18(1):27-33.
49. Jeffe DB, Meredith KL, Mundy LM, Fraser VJ. Factors associated with HIV-infected patients' recognition and use of HIV medications. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:350-360.
50. Mugavero MJ, Norton WE, Saag MS. Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis. 2011; 52(suppl 2):S238-S246.
51. Williams DR, Mohammed SA Discrimination and racial disparities in health: evidence and needed research. J Behav Med. 2009;32(1):20-47.
52. Kahn JG, Zhang X, Cross LT, Palacio H, Birkhead GS, Morin SF. Access to and use of HIV antiretroviral therapy: variation by race/ethnicity in two public insurance programs in the U.S. Public Health Rep. 2002; 117:252-262.
53. Fordyce EJ, Singh TP, Nash D, Gallagher B, Forlenza S. Survival rates in NYC in the era of combination ART. J Acquir Immune Defic Syndr. 2002;30(1):111-118.
54. Joy R, Druyts EF, Brandson EK, et al. Impact of neighborhood-level socioeconomic status on HIV disease progression in universal health care setting. J Acquir Immune Defic Syndr. 2008;47(4):500-505.
55. Rapiti E, Porta D, Forastiere F, Fusco D. Perucci CA for the Lazio AIDS Surveillance Collaborative Group. Socioeconomic status and survival of persons with AIDS before and after the introduction of highly active antiretroviral therapy. Epidemiology. 2000;11(5):496-501.
56. Wood E, Montaner JS, Chan K, et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS. 2002;16(15):2065-2072.
57. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37(5):613-627.
58. Fields-Gardner C, Campa A Position of the American Dietetic Association: nutrition intervention and human immunodeficiency virus infection. J Am Diet Assoc. 2010;110:1105-1119.
59. Yahiaoui A, McGough EL, Voss JG. Development of evidence-based exercise recommendations for older HIV-infected patients. J Assoc Nurses AIDS Care. 2012; 23(3):204-219.
60. Chen SY, Moss WJ, Pipkin SS, McFarland W. A novel use of AIDS surveillance data to assess the impact of initial treatment regimen on survival. Int J STD AIDS. 2009;20(5):330-335.
61. Cunningham WE, Andersen RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with Human Immunodeficiency virus receiving care in the United States. Med Care. 1999;37(12):1270-1281.
62. Cunningham WE, Hays RD, Duan N, et al. The effect of socioeconomic status on the survival of people receiving care for HIV infection in the United States. J Health Care Poor Underserved 2005;16:655-676.
63. Hall HI, McDavid K, Ling Q, Sloggett A Determinants of progression to AIDS or death after HIV diagnosis, United States 1996 to 2001. Ann Epidemiol. 2006;16(11):824-833.
64. Abraído-Lanza AF, Dohrenwend BP, Ng-Mak DS, Turner JB. The Latino Mortality Paradox: A test of the "Salmon Bias" and Healthy Migrant Hypothesis. Am J Public Health. 1999;89(10):1543-1548.
65. Sorlie PD, Backlund E, Johnson NJ, Rogot E. Mortality by Hispanic status in the United States. JAMA. 1993;270(20):2464-2468.
66. Miniño AM, Murphy SL, Xu J, Kochanek KD. Deaths: Final data for 2008. Natl Vital Stat Rep. 2011;59(10): 1-126. Available at http://www.cdc.gov/ nchs/data/nvsr/nvsr59/nvsr59-10.pdf. Accessed July 29, 2011.
67. Morin SF, Sengupta S, Cozen M, et al. Responding to racial and ethnic disparities in use of HIV drugs: analysis of state policies. Public Health Rep. 2002;117(3):263-272.
68. Kaiser Family Foundation. AIDS drug assistance programs (ADAPs) with waiting lists or other cost-containment strategies as of November 2011. Available at: http://www.statehealthfacts.org. Accessed January 4, 2012.